BioCard™

About us

Precision diagnostics, anywhere — powered by BioCard™ innovation

Bio-Diagnostics is a family-owned UK diagnostics company founded in 1979 by the late Philip Mico and run for the last 25 years by his son, Simon Mico. For over 45 years, we’ve built a strong reputation for reliable science, high-quality manufacturing, and ongoing innovation, today driven by our unique patented BioCard™ platform. The future alternative to lateral flow, which brings laboratory accuracy to any location.

Our work spans four main areas: allergy, dermatology, immunology, and vaccine management, specifically COVID-19.

We also offer a range of services including product distribution, contract manufacturing, laboratory testing, and research and development.

We are one of very few UK-based biotech companies with the full capability to research, develop, and manufacture diagnostic tests entirely in-house. Our ISO 13485-accredited laboratory, integrated manufacturing department, and in-house despatch and logistics operation allow us to control every aspect of product quality and delivery.

Our flagship innovation, the BioCard™, is a point-of-care diagnostic tool that delivers rapid, accurate results across a range of applications. During the COVID-19 pandemic, we successfully developed and launched a COVID-19 BioCard™ with >99.5% accuracy, demonstrating our ability to rapidly respond to global health challenges. It remains the only technology to monitor waning immunity to Covid-19 by detecting the full complement of spike specific antibodies vaccines and infection elicit.

We also manufacture the FDA-approved BioCardHSV-2 kit. Our technology is specifically featured in the CDC’s 2021 Sexually Transmitted Infections Treatment Guidelines, testament to its clinical relevance and effectiveness to aid the diagnosis of some 60 million HSV-2 infections.

In addition to human diagnostics, we are now collaborating with the University of Bristol to develop BioCards for plant disease diagnostics, an innovation that could significantly increase crop yields, with 40% otherwise lost. A continued development path which will transform agricultural disease management.

Our allergy diagnostics division, with POC allergy testing, and globally accessible laboratory services, continues to support both national healthcare and private clinicians around the world, aiming to close the gap in allergy awareness and care between the UK and leading European and international countries.